Alemtuzumab, an anti-CD52 depletion antibody, is already FDA-approved for the treatment of multiple sclerosis and has potential for use in the treatment of acute lymphoblastic leukaemia and myeloid leukaemia [32–34]. The gene discussed is CD52; the disease is acute lymphoblastic leukemia.